A trial tested AMD3100 in patients with colorectal and pancreatic cancer, resulting in decreased tumor markers (circulating tumor DNA and IL-8) and changes in immune cells (reduced number of CAFs and increased number of effector TILs/NK cells) [503–505]. Here, CXCL8 is linked to pancreatic neoplasm.